255 related articles for article (PubMed ID: 11857423)
1. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.
Lokeshwar BL; Selzer MG; Zhu BQ; Block NL; Golub LM
Int J Cancer; 2002 Mar; 98(2):297-309. PubMed ID: 11857423
[TBL] [Abstract][Full Text] [Related]
2. MMP inhibition in prostate cancer.
Lokeshwar BL
Ann N Y Acad Sci; 1999 Jun; 878():271-89. PubMed ID: 10415736
[TBL] [Abstract][Full Text] [Related]
3. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.
Lokeshwar BL
Pharmacol Res; 2011 Feb; 63(2):146-50. PubMed ID: 21093590
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3).
Lokeshwar BL; Escatel E; Zhu B
Curr Med Chem; 2001 Feb; 8(3):271-9. PubMed ID: 11172682
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell invasiveness by chemically modified tetracyclines.
Gu Y; Lee HM; Roemer EJ; Musacchia L; Golub LM; Simon SR
Curr Med Chem; 2001 Feb; 8(3):261-70. PubMed ID: 11172681
[TBL] [Abstract][Full Text] [Related]
7. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer.
Lee HM; Golub LM; Cao J; Teronen O; Laitinen M; Salo T; Zucker S; Sorsa T
Curr Med Chem; 2001 Feb; 8(3):257-60. PubMed ID: 11172680
[TBL] [Abstract][Full Text] [Related]
8. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.
Lokeshwar BL; Houston-Clark HL; Selzer MG; Block NL; Golub LM
Adv Dent Res; 1998 Nov; 12(2):97-102. PubMed ID: 9972130
[No Abstract] [Full Text] [Related]
9. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis.
Seftor RE; Seftor EA; De Larco JE; Kleiner DE; Leferson J; Stetler-Stevenson WG; McNamara TF; Golub LM; Hendrix MJ
Clin Exp Metastasis; 1998 Apr; 16(3):217-25. PubMed ID: 9568639
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
Grenier D; Plamondon P; Sorsa T; Lee HM; McNamara T; Ramamurthy NS; Golub LM; Teronen O; Mayrand D
J Periodontol; 2002 Jan; 73(1):79-85. PubMed ID: 11846203
[TBL] [Abstract][Full Text] [Related]
11. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory impacts of chemically modified tetracycline-3 and underlying mechanism in human cervical cancer cells.
Zhao L; Xu J; Yang Y; Chong Y; Liu C; Jiao Y; Fan S
Anticancer Drugs; 2013 Sep; 24(8):799-809. PubMed ID: 23722439
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines.
Curci JA; Petrinec D; Liao S; Golub LM; Thompson RW
J Vasc Surg; 1998 Dec; 28(6):1082-93. PubMed ID: 9845660
[TBL] [Abstract][Full Text] [Related]
14. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.
Gu Y; Lee HM; Simon SR; Golub LM
Pharmacol Res; 2011 Dec; 64(6):595-601. PubMed ID: 21651982
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines.
Gu Y; Lee HM; Golub LM; Sorsa T; Konttinen YT; Simon SR
Ann Med; 2005; 37(6):450-60. PubMed ID: 16203617
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
17. Chemically modified tetracyclines induce apoptosis in cultured mast cells.
Sandler C; Nurmi K; Lindstedt KA; Sorsa T; Golub LM; Kovanen PT; Eklund KK
Int Immunopharmacol; 2005 Oct; 5(11):1611-21. PubMed ID: 16039551
[TBL] [Abstract][Full Text] [Related]
18. Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.
Meng Q; Xu J; Goldberg ID; Rosen EM; Greenwald RA; Fan S
Clin Exp Metastasis; 2000; 18(2):139-46. PubMed ID: 11235989
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
20. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
Duivenvoorden WC; Hirte HW; Singh G
Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
